Streetbeat News

Analyst Ratings

QTWO

In the last quarter, Q2 Holdings (NYSE:QTWO) received 6 bullish, 1 somewhat bullish, 4 indifferent, and 2 somewhat bearish ratings from 13 analysts. The average 12-month price target is $28.92, representing an 18.42% decrease from the previous average of $35.45.

Portfolio Pulse from Benzinga Insights

May 31, 2023 | 2:03 pm

CXM

Over the past 3 months, 5 analysts have published their opinions on Sprinklr (NYSE:CXM) stock, with 2 being somewhat bullish and 3 indifferent. The average 12-month price target for the company is $14.4, with a high of $20.00 and a low of $11.00.

Portfolio Pulse from Benzinga Insights

May 31, 2023 | 2:02 pm

TWLO

Over the past 3 months, 14 analysts have published their opinion on Twilio (NYSE:TWLO) stock, with an average 12-month price target of $63.43, a 22.49% decrease from the previous average price target of $81.83.

Portfolio Pulse from Benzinga Insights

May 31, 2023 | 2:00 pm

MDXH

TD Cowen analyst Dan Brennan initiates coverage on MDxHealth (NASDAQ:MDXH) with an Outperform rating and announces a price target of $7.

Portfolio Pulse from richadhand@benzinga.com

May 31, 2023 | 1:50 pm

PRCT

William Blair analyst Brandon Vazquez initiates coverage on PROCEPT BioRobotics (NASDAQ:PRCT) with an Outperform rating.

Portfolio Pulse from richadhand@benzinga.com

May 31, 2023 | 1:49 pm

SGA

Noble Capital Markets has initiated coverage on Saga Communications (NASDAQ:SGA) with an Outperform rating and a price target of $27.

Portfolio Pulse from richadhand@benzinga.com

May 31, 2023 | 1:48 pm

ACNB

Hovde Group analyst David Bishop initiates coverage on ACNB (NASDAQ:ACNB) with an Outperform rating and announces a price target of $36.

Portfolio Pulse from richadhand@benzinga.com

May 31, 2023 | 1:46 pm

NIR

Northland Capital Markets analyst Michael Latimore initiates coverage on Near Intelligence (NASDAQ:NIR) with an Outperform rating and a price target of $8.

Portfolio Pulse from richadhand@benzinga.com

May 31, 2023 | 1:44 pm

OCEA

Taglich Brothers has initiated coverage of Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company focused on commercializing innovative therapeutic assets from research universities and medical centers. Ocean Biomedical's initial programs include candidates for lung cancer, brain cancer, pulmonary fibrosis, and malaria prevention and treatment.

Portfolio Pulse from Happy Mohamed

May 31, 2023 | 1:38 pm